Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer
Addition of a brachytherapy boost to external beam radiation therapy (EBRT) reduces prostate cancer (PCa) recurrence at the expense of genitourinary (GU) toxicity. Whether brachytherapy boost technique, specifically low-dose-rate (LDR-BT) versus high-dose-rate (HDR-BT), impacts treatment-related toxicity is unclear.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Vishal R. Dhere, Benjamin W. Fischer-Valuck, Subir Goyal, Yuan Liu, Tiffany M. Morgan, Elizabeth Ghavidel, Drew M. Moghanaki, Bruce W. Hershatter, Pretesh R. Patel, Ashesh B. Jani, Karen D. Godette, Peter J. Rossi, Sagar A. Patel Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | External Beam Therapy | Prostate Cancer | Radiation Therapy | Toxicology